Paroxysmal Nocturnal Haemoglobinuria (PNH) is a rare acquired disease of the blood, which affects an annual rate of 1-2 cases per million. It is characterised by anemia due to destruction of red blood cells in the bloodstream, red urine due to the appearance of haemoglobin in the urine and thrombosis. The disease may occur at any age but it preferentially affects young adults. Only bone marrow transplantation permanently abolishes the hematopoietic defect, but recently a long term study showed the clinical benefits after 8 years of continued treatment with Eculizumab.
The collaboration agreement was signed by Dr. Joan Lluis Vives-Corrons, coordinator of ENERCA, and Mr. Jordi Cruz Villalba, President of the Spanish PNH Association. It will be the framework for both institutions to promote patient and professional-oriented activities to raise awareness about the disease and empower patients for a better management of their condition.